PERSEPHONE — implications for clinical practice in 2019

Nature Reviews Clinical Oncology, Published online: 24 July 2019; doi:10.1038/s41571-019-0256-7Five randomized trials have been conducted to prove that shorter duration of trastuzumab treatment (9 weeks or 6 months) can replace the standard duration (1 year). The results of PERSEPHONE, the most recent trial, suggest that the efficacy of a 6-month treatment is non-inferior to that of 1 year, although not for all patients. We discuss these results in the context of current treatment standards.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research